+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 10 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the combined use of finerenone and empagliflozin compared to usual care to assess their safety and effectiveness in patients hospitalized with heart failure. This international, randomized, controlled, open-label trial aims to study an early, intensive management approach for heart failure treatment. Participants will be assigned to receive either the combination of oral finerenone plus oral empagliflozin or usual care. The study focuses on treatment during hospitalization and shortly after, comparing these approaches to understand the clinical benefits and risks over a six-month period. During the trial, participants will be monitored for clinical outcomes including serious adverse events and events leading to treatment discontinuation. Researchers will measure heart failure events, symptom changes using the Kansas City Cardiomyopathy Questionnaire, and overall survival up to six months. Safety and efficacy data will be collected throughout the study period ending in November 2027.

Age: 18Years +All GendersPhase 3
140 locations
R

Actively Recruiting

Researchers are evaluating the effectiveness and safety of finerenone compared to a placebo in patients hospitalized with acute decompensated heart failure who have mildly reduced or preserved left ventricular ejection fraction. This international, randomized, double-blind, placebo-controlled Phase 3 trial aims to study how finerenone affects morbidity and mortality in these patients. Participants will be randomly assigned to receive either oral finerenone or a matching placebo. The study is event-driven and will monitor patients for up to approximately 30 months. It includes ongoing evaluation of heart failure events, cardiovascular death, and adverse events related to the study drug. Both groups will be observed throughout this period to compare outcomes. During the trial, participants will undergo regular assessments including monitoring for heart failure events, cardiovascular death, and serious adverse events. The study will also measure changes in symptom scores using the Kansas City Cardiomyopathy Questionnaire at 6 months. Safety and tolerability will be closely tracked, including adverse events leading to discontinuation of the study drug. Participants will be followed for up to 30 months to assess long-term effects.

Age: 18Years +All GendersPhase 3
356 locations
S

Actively Recruiting

Researchers are evaluating finerenone compared to a placebo to assess the effectiveness and safety of treatment in patients with heart failure and reduced ejection fraction HFrEF who cannot tolerate or are not eligible for steroidal mineralocorticoid receptor antagonists sMRA. This international study is a randomized, double-blind, placebo-controlled trial focused on this specific group of heart failure patients. Participants will be randomly assigned to receive either oral finerenone or a matching placebo. The study uses a parallel design and treatment will be monitored for up to about 30 months. During this time, researchers will track cardiovascular events, heart failure events, and any serious or adverse events leading to discontinuation of the study drug. Throughout the study, participants will undergo regular assessments including symptom questionnaires and monitoring for cardiovascular outcomes and safety. The main outcomes include the time to the first cardiovascular death or heart failure event and the number of serious adverse events. The study also tracks changes in symptom scores over six months and overall survival. Participants will be followed closely during treatment and after to understand both efficacy and safety.

Age: 18Years +All GendersPhase 3
176 locations
E

Actively Recruiting

Researchers are evaluating how effective dry needling combined with two different stretching methods is for people who have had neck pain for more than 3 months. The study aims to find out which treatment combination provides faster pain relief, improves neck movement, and reduces disability in those with neck pain. The trial involves comparing these two approaches to better understand their effects on upper trapezius muscle trigger points. Participants will be randomly divided into two groups. One group will receive dry needling plus passive stretching, while the other group will receive dry needling combined with muscle energy technique. Treatments will be given twice a week for two weeks. Before and after the interventions, researchers will assess pain using a visual scale, measure neck range of motion with a goniometer, and evaluate disability levels using a neck disability index. Participants will be interviewed and assessed at the start and after the last treatment session. Researchers will collect data on pain, neck movement, and disability to compare results between the two groups. Statistical analysis will be performed to understand the treatment effects. The entire study participation lasts about two weeks, during which safety and effectiveness of the treatments will be monitored.

Age: 18Years - 60YearsAll GendersPhase Not Applicable
1 location
E

Actively Recruiting

Researchers are investigating adults in Sri Lanka with heart failure with reduced ejection fraction HFrEF to assess how an HFrEF polypill strategy affects the combined rate of cardiovascular death and repeated heart failure hospitalizations compared to usual care. The study evaluates this over at least 12 months of follow-up and includes secondary outcomes such as mortality rates, heart function changes via echocardiogram, and quality of life measures. Participants will be randomly assigned to two groups one receives usual care with guideline-directed medications dispensed at no charge when available, while the other receives a combined polypill containing bisoprolol, losartan, eplerenone, and dapagliflozin in three possible dose strengths. The polypill dose will be adjusted during scheduled visits to reach the highest tolerated dose, aiming for the strongest dose by study end. During the study, participants undergo regular visits at 1, 3, 6, 9, and 12 months and every 3 months thereafter, averaging 18 months total. Researchers will monitor heart function, biomarker levels, quality of life questionnaires, medication adherence, and safety outcomes including adverse events and laboratory measures like potassium and creatinine levels. The study includes detailed assessments to evaluate treatment persistence, dose optimization, and overall health impact over time.

Age: 18Years +All GendersPhase 3
12 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety and tolerability of Empagliflozin, with or without metformin, in patients with Type II Diabetes Mellitus within the Pakistani population. This open-label, prospective, observational, single-arm, multi-center post-marketing surveillance study aims to monitor side effects such as hypoglycemia, dehydration, urinary tract infections, and gastrointestinal symptoms. The study is sponsored by Getz Pharma and includes adults aged 18 to 65 years with uncontrolled diabetes despite oral antidiabetic treatment and lifestyle modifications. Participants will receive Empagliflozin alone or combined with metformin in varying doses. The study includes three follow-up visits after starting therapy the first at 4 to 6 weeks, the second at 12 weeks, and the third at 24 weeks. Laboratory tests such as HbA1c, fasting blood glucose, renal function tests, and urine routine examination will be conducted at reputable clinical labs, with participants receiving discounts for these tests. During the study, participants will be closely monitored for safety and efficacy outcomes over six months from enrollment. Assessments include clinical evaluations and laboratory investigations to track diabetes control and potential side effects. The total study duration is 12 months, with the primary outcomes focusing on safety and tolerability at six months and secondary outcomes on efficacy. Participants health will be carefully observed throughout the follow-up period.

Age: 18Years - 65YearsAll GendersPhase 4
6 locations
S

Actively Recruiting

Researchers are evaluating the effects of the SGLT2 inhibitor dapagliflozin compared to metformin on the annual decline in kidney function, measured by eGFR, in people with Type 2 Diabetes. This Phase 3, randomized, double-blind trial is conducted in primary care and community sites in Australia and tertiary care centers in Sri Lanka. The purpose is to understand which first-line therapy may better prevent kidney decline in this population. After a 4-week active run-in period, participants will be randomly assigned to one of two groups one group will take dapagliflozin 10 mg once daily with placebo metformin tablets, and the other group will take metformin XR 2000 mg once daily with placebo dapagliflozin tablets. Treatment will continue for 2 years under quadruple masking to maintain study integrity. During the study, participants will undergo assessments including kidney function tests eGFR, serum creatinine, urine albumin creatinine ratio, blood sugar measurements HbA1C, fasting glucose, blood pressure monitoring, body weight check, and quality of life evaluations using the EQ-5D-5L. Mental health symptoms such as anxiety and depression will also be measured with the HADS questionnaire. The primary outcome is the rate of eGFR decline over 24 months, with safety and other health indicators monitored throughout the study period.

Age: 18Years +All GendersPhase 3
8 locations
S

Actively Recruiting

Researchers are studying the safety, effectiveness, and how the body processes the investigational drug WAL0921 in adults with various glomerular kidney diseases and proteinuria. These include diabetic nephropathy and rare conditions such as primary focal segmental glomerulosclerosis, treatment-resistant minimal change disease, primary immunoglobulin A nephropathy, and primary membranous nephropathy. This is a Phase 2, randomized, double-blind, placebo-controlled study conducted at multiple centers to evaluate WAL0921 compared to a placebo. Participants will be randomly assigned to receive either the investigational drug WAL0921 or a placebo through an intravenous infusion every two weeks for a total of seven infusions. The study includes a treatment period followed by a 24-week follow-up after the last infusion to monitor participants. The treatments are given in parallel groups to compare their effects and safety. During the study, participants will undergo regular assessments including monitoring for adverse events from the start through Week 36. Researchers will also measure changes in albuminuria, proteinuria, and kidney function markers such as estimated glomerular filtration rate over 24 weeks. These evaluations help determine how the drug affects kidney disease markers and overall safety. The total participation time includes treatment and follow-up periods lasting several months.

Age: 18Years - 75YearsAll GendersPhase 2
50 locations
C

Actively Recruiting

Researchers are conducting an international, multi-center Phase III trial called CAPTIVATE to study treatments for chronic kidney disease CKD, which affects over 800 million people worldwide and can lead to kidney failure and other serious health problems. The trial aims to identify the best single or combined treatments that can slow CKD progression and reduce the number of people developing kidney failure. CAPTIVATE uses an adaptive platform design allowing multiple therapies to be tested efficiently within a common framework, with the flexibility to add or remove treatments over time. Participants may join one or more treatment domains and receive each study treatment for 2 years. Treatments under study include finerenone tablets taken once daily and semaglutide injections given once weekly, along with their matching placebos. Participants will attend scheduled study visits at approximately 1 month, 3 months, 6 months, 12 months, 18 months, and 2 years after starting treatment, with a final visit one month after treatment ends. The trial is ongoing and will continue recruiting for several years. During the study, participants undergo blood and urine tests, safety checks, and assessments of treatment adherence at regular visits. The research team collects information on overall health status every 5 years. The primary outcomes focus on treatment effects measured from randomization through week 108, with various secondary outcomes tracked throughout the study. Safety is monitored continuously, and participants remain under their usual care alongside the trial procedures.

Age: 18Years +All GendersPhase 3
51 locations
S

Actively Recruiting

Researchers are evaluating the Lupus Low Disease Activity State LLDAS in patients with Systemic Lupus Erythematosus SLE, a complex autoimmune disease affecting multiple organs and causing serious health problems. The study aims to see if achieving LLDAS is linked to better outcomes, including less organ damage, as traditional remission is rare and difficult to measure in lupus patients. The study is international and multi-center, led by the Asia Pacific Lupus Collaboration and sponsored by Monash University. Patients with SLE will be followed for approximately five years. During this time, researchers will collect regular data on disease activity and treatment to assess whether patients meet the LLDAS criteria. Annual assessments will also record lupus-related organ damage using the SLICC-ACR Damage Index and quality of life using the Short Form 36 version 2. At the end of the study, the researchers will evaluate if sustained LLDAS protects against organ damage. Participants will have their clinical and treatment data monitored regularly over several years. The study will measure outcomes including organ damage progression, quality of life, and mortality. These long-term assessments will help determine whether LLDAS is a useful target in managing lupus. The total participation time is about five to ten years, allowing detailed tracking of disease impact and patient well-being.

Age: 18Years +All Genders
20 locations